

ACKNOWLEDGMENTS

We thank Research Biochemicals International (Natick, MA) for supplying the trimethylstannyl precursor of [^{123}I] βCIT -FP, and Dr. Jerry Porter of Nordion International (Vancouver, BC) for the radioiodine used in the SPECT studies. This work was supported by grants from the Parkinson Disease Foundation and the National Parkinson Foundation. Drs. Ishikawa and Kazumata are Veola T. Kerr Fellows of the Parkinson Disease Foundation. We also thank Drs. Abdel Belakhlef, J. Robert Dahl, William Robeson, Ralph Mattachieri and Archy Yee for technical support, and Debra Segal for administrative assistance. We are grateful to Dr. Stephen J. Kish for many helpful comments concerning this work.

REFERENCES

- Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. *Neurology* 1993;43(suppl 6):S6-S16.
- Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with ^{18}F -fluorodeoxyglucose and PET. *Neurology* 1995;45:1995-2004.
- Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in Parkinsonism: comparative studies and clinical correlations. *J Nucl Med* 1994;35:955-963.
- Ishikawa T, Dhawan V, Chaly T, et al. The clinical significance of dopa decarboxylase activity in Parkinson's disease. *J Nucl Med* 1996;37:216-222.
- Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary ^{18}F -fluorodeoxyglucose and ^{18}F -fluorodopa positron emission tomography studies. *Mov Disord* 1990;5:203-213.
- Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. *Proc Natl Acad Sci* 1993;90:11965-11969.
- Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [^{123}I] βCIT : pharmacological characterization of brain uptake in nonhuman primates. *Synapse* 1993;13:295-309.
- Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic and equilibrium analyses of in vivo [^{123}I] βCIT binding to dopamine transporters in healthy human subjects. *J Cereb Blood Flow Metab* 1994;14:982-994.
- Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123- βCIT SPECT. *J Nucl Med* 1995;36:1175-1181.
- Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [^{123}I] βCIT striatal uptake correlates with symptom severity in Parkinson's disease. *Ann Neurol* 1995;38:589-598.
- Neumeyer JL, Wang S, Gao Y, et al. N- ω -fluoroalkyl analogs of (1R)-2 β -carbomethoxy-3 β -(4-iodophenyl)tropane ($\beta\text{-CIT}$): radiotracers for PET and SPECT imaging of dopamine transporters. *J Med Chem* 1994;37:1558-1561.
- Baldwin RM, Zea-Ponce Y, Al-Tikriti MS, et al. Regional brain uptake and pharmacokinetics of [^{123}I]N- ω -fluoroalkyl-2 β -carboxy-3 β -(4-iodophenyl)nortropane esters in baboons. *Nucl Med Biol* 1995;21:211-219.
- Abi-Dargham A, Gandelman M, DeErausquin G, et al. SPECT imaging of dopamine transporters in human brain with iodine-123 fluoroalkyl analogs of βCIT . *J Nucl Med* 1996;37:1129-1133.
- Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. *Neurology* 1967;17:21-25.
- Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. *Recent developments in Parkinson's disease*, vol. 2. Macmillan, Floral Park, New Jersey 1987:293-304.
- DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. *J Nucl Med* 1994;35:1398-1406.
- Hariz MI, Erikson AT. Reproducibility of repeated mounting of a noninvasive CT/MRI stereotaxic. *Appl Neurophysiol* 1986;49:336-347.
- Luxen A, Milton P, Bida GT, et al. Remote, semiautomated production of 6-[^{18}F]fluoro-L-dopa for human studies with PET. *Appl Radiat Isot* 1990;41:275-281.
- Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. *J Cereb Blood Flow Metab* 1983;3:1-7.
- Resnick SM, Karp JS, Turetsky B, Gur RE. Comparison of anatomically-defined versus physiologically-based regional localization: effects on PET-FDG quantitation. *J Nucl Med* 1993;34:2201-2207.
- Anderson TW. *An introduction to multivariate statistical analysis*. New York: John Wiley and Sons; 1984.
- Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal ^{18}F -Dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. *Ann Neurol* 1990;28:547-555.
- Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson's disease from normality. *Arch Neurol* 1994;51:237-243.
- Dhawan V, Ishikawa T, Patlak C, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease: modeling issues. *J Nucl Med* 1996;37:209-216.
- Fearnley JM, Lees AJ. Aging, Parkinson's disease: substantia nigra regional selectivity. *Brain* 1991;114:2283-2301.
- Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. *Ann Neurol* 1994;36:237-239.
- Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age in healthy subjects. *J Nucl Med* 1996;37:in press.

- Murphy DGM, DeCarli C, Schapiro MB, et al. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. *Arch Neurol* 1992;49:839-845.
- Martin WRW, Palmer MR, Patlak CS, et al. Nigrostriatal function in man studied with positron emission tomography. *Ann Neurol* 1989;26:535-542.
- Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. *J Nucl Med* 1994;35:18-23.
- Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak SJ. Striatal function in normal aging: implications for Parkinson's disease. *Ann Neurol* 1990;28:799-804.
- Eidelberg D, Takikawa S, Dhawan V, et al. Striatal ^{18}F -dopa uptake: absence of an aging effect. *J Cereb Blood Flow Metab* 1993;13:881-888.
- Eidelberg D, Dhawan V, Moeller JR. An aging effect in striatal fluorodopa uptake? Large versus small ROIs. *J Cereb Blood Flow Metab* 1994;14:882-883.
- Gjedde A, Reith J, Dyve S. Dopa decarboxylase activity of the living brain. *Neurobiology* 1991;88:2272-2275.
- Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal DOPA decarboxylase in aging: disparity between postmortem and positron emission tomography studies? *Ann Neurol* 1995;38:260-264.
- Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with ^{11}C -WIN 35, 428 reveals marked declines in mild Parkinson's disease. *Ann Neurol* 1993;34:423-431.
- Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. *Brain* 1994;117:509-516.

ERRATUM

In the human studies article by Juweid et al. (September 1996 issue of *JNM*, pages 1504-1510), tumor volumes in the Abstract and Results Section were printed incorrectly. In the Abstract, the correct statement is "Targeting of all tumor lesions >0.5 cm in diameter, not 70.5 cm in diameter] was possible in nine patients etc.". The same applies to the statement in Results under "Targeting", "All disease sites >0.5 cm in diameter [not 0.5 cm] were visualized in 9 of 13 patients studied". Also, in Table 2, the information on Patients 1125 and 1318 was transposed. The corrected table is printed below.

TABLE 2
Therapeutic Results in Initial Assessable Patients

Patient no.	No. of treatments	Initial red marrow dose (cGy)	Anti-tumor effects (duration)
1142	1	55	Progression
1063	1	55	Stable disease (1 mo)
1124	1	108	Progression
775	4	150*	Stabilization of disease (7 mo) (Regression of small pulmonary nodules and stable adrenal and bony metastases)
1125	1	191	Progression
1318	2	194*	Stabilization of disease (5 mo) [25% reduction in left cervical and stable right cervical adenopathy. Stable CEA and calcitonin (11 mo)]
1047	1	250	Progression
991	2	450	Stabilization of disease (3.5 mo)
1014	3	450	Stabilization of disease (5 mo)
1036	3	450	Stabilization of disease (6.5 mo)
1217	3	450	Stabilization of disease (7 mo)
1156	1	450	Progression
1186	1	450	Progression

*Patient received two additional RAIT cycles in 2-mo intervals, delivering a total red marrow dose of 501 cGy.

[†]Red marrow dose after the second RAIT, 10 mo after the first RAIT, delivering a total dose of 150 cGy to the marrow.